DG
AURA icon

David Goel’s Aura Biosciences AURA Stock Holding History

David Goel’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6,922,870
Closed -$46.3M – 1
2026
Q1 		$46.3M Hold
6,922,870
– – 100% 1
2025
Q4 		$37.7M Hold
6,922,870
– – 65.48% 1
2025
Q3 		$42.8M Hold
6,922,870
– – 40.08% 2
2025
Q2 		$43.3M Hold
6,922,870
– – 19.45% 2
2025
Q1 		$40.6M Hold
6,922,870
– – 11.68% 2
2024
Q4 		$56.9M Hold
6,922,870
– – 2.65% 4
2024
Q3 		$61.7M Hold
6,922,870
– – 2.94% 4
2024
Q2 		$52.3M Hold
6,922,870
– – 0.4% 17
2024
Q1 		$54.3M Hold
6,922,870
– – 0.5% 18
2023
Q4 		$61.3M Buy
6,922,870
+1,560,000
+29% +$13.2M 0.63% 13
2023
Q3 		$48.1M Hold
5,362,870
– – 0.58% 15
2023
Q2 		$66.2M Hold
5,362,870
– – 0.77% 14
2023
Q1 		$49.8M Hold
5,362,870
– – 0.68% 14
2022
Q4 		$56.3M Buy
5,362,870
+1,250,000
+30% +$15.9M 1.08% 15
2022
Q3 		$74.5M Hold
4,112,870
– – 1.43% 15
2022
Q2 		$58.3M Hold
4,112,870
– – 1.32% 15
2022
Q1 		$90.5M Hold
4,112,870
– – 1.09% 18
2021
Q4 		$69.8M Buy
+4,112,870
New +$73.5M 0.78% 20

Other funds holding AURA

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

David Goel's AURA Position: Q2 2026 in Review

David Goel sold out of Aura Biosciences (AURA) in Q2 2026, closing a stake of 6,922,870 shares — an estimated $46.3M sold.

David Goel first reported a position in AURA in Q4 2021 and held it in 18 quarters. The position peaked at $90.5M in Q1 2022. 145 funds tracked by Wall St. Rank hold AURA as of Q2 2026.

  • David Goel reported no remaining Aura Biosciences position as of Q2 2026 after selling out during the quarter.
  • David Goel sold 6,922,870 Aura Biosciences shares in Q2 2026, an estimated $46.3M.
  • David Goel first reported a position in Aura Biosciences in Q4 2021 and held it in 18 quarters.
  • David Goel's Aura Biosciences position peaked at $90.5M in Q1 2022.
  • 145 funds tracked by Wall St. Rank held Aura Biosciences as of Q2 2026.

Based on Matrix Capital Management Company's 13F filing for Q2 2026.